MarketPeel
Insider Trading Intelligence
NB

Nicholas A.j. Botwood

SNDX
HEAD OF R&D, CMO · SYNDAX PHARMACEUTICALS INC · CIK 0002066784
FILING MIX · LIFETIME80%/20%
BUYS
8
SELLS
2
TOTAL VALUE
$4.99M
COMPANIES
1
ACTIVE SINCE
May 2025
HOLDINGS NOW
60,885
AVG SELL PX
$18.07
TRADE KIND
SHOWING 10 / 10
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 1 pending
Forward-return performance of every backtestable P/S trade by Nicholas A.j. Botwood, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%+8.84%-2.54%+11.38%+11.38%
14d1+100.00%+16.46%-0.81%+17.27%+17.27%
30d1+100.00%+10.39%+1.43%+8.96%+8.96%
60d1+100.00%+1.77%+4.70%-2.93%-2.93%
90d1+100.00%+62.76%+8.54%+54.22%+54.22%
180d1+100.00%+85.53%+15.01%+70.52%+70.52%
1y1+100.00%+130.83%+24.93%+105.90%+105.90%
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SNDX · 60,885 shares · as of Jun 12, 2026
036,17572,350108,525144,7002026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2025
2025
2025
2026
2026
FLOW · 8 buys / 2 sellsCOVERAGE · 5 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
SNDX
SYNDAX PHARMACEUTICALS INC
SALE10b5-1
10b5-1 plan
31,235$18.14$566.6K60,885Jun 12, 2026Jun 12, 2026View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
Head of R&D, CMO
31,235$13.82$431.7K92,120Jun 12, 2026Jun 12, 2026View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
Head of R&D, CMO
31,2350Jun 12, 2026Jun 12, 2026View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE10b5-1
10b5-1 plan
34,280$18.00$617.0K60,885Jun 11, 2026Jun 12, 2026View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
Head of R&D, CMO
22,515$13.82$311.2K95,165Jun 11, 2026Jun 12, 2026View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
Head of R&D, CMO
22,5150Jun 11, 2026Jun 12, 2026View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
24,00059,165Feb 4, 2026Feb 6, 2026View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
36,00095,165Feb 4, 2026Feb 6, 2026View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
144,700$20.43$2.96M144,700Feb 4, 2026Feb 6, 2026View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
Head of R&D, CMO
11,765$9.00$105.8K35,165May 16, 2025May 19, 2025View →
Other insiders · SNDX
Loading peer insiders…
About this filer
CIK 0002066784
ROLE
Head of R&D, CMO
PRIMARY
SNDX
COMPANIES
1
ACTIVE SINCE
May 2025
MARKETPEEL · /INSIDER/0002066784DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback